Metformin prolonged the survival of diffuse large B-cell lymphoma and grade 3b follicular lymphoma patients responding to first-line treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone: a prospective phase II clinical trial | Zendy

Xing Fan | Zendy; Huijuan Zhong | Zendy; Bing-Bing Zhao | Zendy; Bin-Shen Ou Yang | Zendy; Yan Zhao | Zendy; Jing Ye | Zendy; Yiming Lu | Zendy; ChaoFu Wang | Zendy; Xiong Hong | Zendy; SaiJuan Chen | Zendy; Anne Janin | Zendy; Li Wang | Zendy; Weili Zhao | Zendy

Open Access

Metformin prolonged the survival of diffuse large B-cell lymphoma and grade 3b follicular lymphoma patients responding to first-line treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone: a prospective phase II clinical trial

Author(s) -

Xing Fan,

Huijuan Zhong,

Bing-Bing Zhao,

Bin-Shen Ou Yang,

Yan Zhao,

Jing Ye,

Yiming Lu,

ChaoFu Wang,

Xiong Hong,

SaiJuan Chen,

Anne Janin,

Li Wang,

Weili Zhao

Publication year - 2018

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2018.07.20

Subject(s) - medicine , vincristine , metformin , rituximab , maintenance therapy , international prognostic index , prednisone , oncology , cyclophosphamide , diffuse large b cell lymphoma , follicular lymphoma , lymphoma , chop , chemotherapy , gastroenterology , insulin

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research